Enterprise Value

430.8M

Cash

26.38M

Avg Qtr Burn

-13.6M

Short % of Float

18.91%

Insider Ownership

1.58%

Institutional Own.

12.83%

Qtr Updated

03/31/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
OCU400 Details
Leber congenital amaurosis, Eye disease

Phase 3

Initiation

Phase 3

Initiation

OCU400 Details
Retinitis Pigmentosa

Phase 3

Initiation

OCU410ST Details
Rare genetic disease, Stargardt disease

Phase 1/2

Data readout

OCU410 Details
Geographic atrophy, Age-related macular degeneration

Phase 1/2

Update

COVAXIN (BBV152) Details
COVID-19, Infectious disease

Failed

Discontinued